In pathologies such as lipid and glucose metabolism disorders, inflammation, obesity, decreased insulin resistance, and atherosclerosis, which may lead to secondary liver damage, the potential benefits of PPAR agonists are well recognized. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.